

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM620568

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, as Collateral Agent		01/13/2021	Bank: SWITZERLAND
RECEIVING PARTY DATA			
Name:	JAGUAR HOLDING COMPANY I		
Street Address:	929 North Front Street		
City:	Wilmington		
State/Country:	DELAWARE		
Postal Code:	28401		
Entity Type:	Corporation: DELAWARE		
Name:	Jaguar Holding Company II		
Street Address:	929 North Front Street		
City:	Wilmington		
State/Country:	DELAWARE		
Postal Code:	28401		
Entity Type:	Corporation: DELAWARE		
Name:	Pharmaceutical Product Development, LLC		
Street Address:	929 North Front Street		
City:	Wilmington		
State/Country:	DELAWARE		
Postal Code:	28401		
Entity Type:	Limited Liability Company: DELAWARE		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Registration Number:	5129408	OPTIMAL RESEARCH INTEGRATED SITE SOLUTIO	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	800-494-5225		
TRADEMARK			

OP \$40.00 5129408

Email: ipteam@cogencyglobal.com
Correspondent Name: Stewart Walsh
Address Line 1: 1025 Vermont Ave NW, Suite 1130
Address Line 2: COGENCY GLOBAL Inc.
Address Line 4: Washington, D.C. 20005

ATTORNEY DOCKET NUMBER: 1315278 TM D

NAME OF SUBMITTER: Hannah Adkins

SIGNATURE: /Hannah Adkins/

DATE SIGNED: 01/15/2021

Total Attachments: 4

source=D PPD - Trademark Release RF 6687.0312 (Executed)#page2.tif

source=D PPD - Trademark Release RF 6687.0312 (Executed)#page3.tif

source=D PPD - Trademark Release RF 6687.0312 (Executed)#page4.tif

source=D PPD - Trademark Release RF 6687.0312 (Executed)#page5.tif

RELEASE OF TRADEMARK SECURITY INTERESTS dated as of January 13, 2021 (this “Release”), by CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, as collateral agent (the “Collateral Agent”) for the Secured Parties, in favor of Optimal Research, LLC (the “Grantor”). Capitalized terms used herein and not otherwise defined shall have the meanings assigned to such terms in the Credit Agreement, the Security Agreement or the IP Security Agreement, as applicable, referred to below.

A. Reference is made to (i) the Credit Agreement dated as of August 18, 2015 (as amended, amended and restated, supplemented or otherwise modified from time to time, the “Credit Agreement”), among Jaguar Holding Company I, a Delaware corporation (“Holdings”), Jaguar Holding Company II, a Delaware corporation (the “Parent Borrower”), Pharmaceutical Product Development, LLC, a Delaware limited liability company (the “Subsidiary Borrower”), the Lenders, the L/C Issuers and the Collateral Agent, (ii) the Security Agreement dated as of August 18, 2015 (as amended, amended and restated, supplemented or otherwise modified from time to time, the “Security Agreement”), among the Grantors from time to time party thereto and the Collateral Agent and (iii) the Intellectual Property Security Agreement dated as of July 1, 2019, among the Grantors listed therein and the Collateral Agent (as amended, amended and restated, supplemented or otherwise modified from time to time, the “IP Security Agreement”) (such documents set forth in clauses (i) through (iii), the “Security Documents”).

B. Pursuant to the Security Documents, the Grantor collaterally assigned, pledged and granted to the Collateral Agent, for the benefit of the Secured Parties, a security interest in, among other property, the Trademark Collateral (as hereinafter defined), which security interest was recorded with the United States Patent & Trademark Office on July 2, 2019 at Reel/Frame 6687/0312.

C. Pursuant to the Payoff Letter dated as of January 12, 2021, among Holdings, the Parent Borrower, the Subsidiary Borrower and the Collateral Agent, the Collateral Agent agreed to release any and all security interests it may have in the Trademark Collateral pursuant to the Security Documents.

Accordingly, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Collateral Agent does hereby release, relinquish and discharge its security interest it has in and to all of the following in each case to the extent created, granted or otherwise established under any Security Document (the “Trademark Collateral”):

All of the Grantor’s right title and interest in and to the following:

- (i) the trademarks and service marks owned by the Grantor, including those set forth on Schedule I hereto, together with the goodwill symbolized thereby;

(ii) all reissues, divisionals, continuations, continuations-in-part, extensions, renewals and reexaminations of any of the foregoing, all rights in the foregoing provided by international treaties or conventions, all rights corresponding thereto throughout the world and all other rights of any kind whatsoever of the Grantor accruing thereunder or pertaining thereto;

(iii) any and all claims for damages and injunctive relief for past, present and future infringement, dilution, misappropriation, violation, misuse or breach with respect to any of the foregoing, with the right, but not the obligation, to sue for and collect, or otherwise recover, such damages; and

(iv) any and all proceeds of, collateral for, income, royalties and other payments now or hereafter due and payable with respect to, and supporting obligations relating to, any and all of the Trademark Collateral of or arising from any of the foregoing.

The Collateral Agent hereby re-assigns to the Grantor any right, title or interest it may have in the Trademark Collateral, without representation or warranty of any kind. The Collateral Agent authorizes the Grantor (or its designee, or any person or entity hereafter having any right title or interest in the Trademark Collateral) to make filings with the United States Patent and Trademark Office and other necessary filings, in each case at the expense of the Grantor, to evidence the release and termination of the Collateral Agent's security interests in the Trademark Collateral.


Sections 4 and 6 of the IP Security Agreement are incorporated herein by reference, *mutatis mutandis*.

[The remainder of this page intentionally left blank]

IN WITNESS WHEREOF, the Collateral Agent has caused this Release to be duly executed as of the day and year first above written.

CREDIT SUISSE AG, CAYMAN ISLANDS
BRANCH, as Collateral Agent,


By



Name: Whitney Gaston

Title: Authorized Signatory

By



Name: Komal Shah

Title: Authorized Signatory

Schedule I

Trademarks

Registered Trademarks

Owner	Mark	Registration Number	Expiration Date
Optimal Research, LLC	OPTIMAL RESEARCH INTEGRATED SITE SOLUTIONS	5,129,408	January 24, 2027

Trademark Applications

None.